BioLargo (NASDAQ:BLGO – Get Free Report) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its peers? We will compare BioLargo to similar businesses based on the strength of its risk, analyst recommendations, valuation, dividends, institutional ownership, earnings and profitability.
Earnings and Valuation
This table compares BioLargo and its peers revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.06 |
BioLargo Competitors | $6.63 billion | $204.21 million | 65.95 |
BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1282 | 1596 | 46 | 2.51 |
As a group, “Chemicals & allied products” companies have a potential upside of 6.99%. Given BioLargo’s peers higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.
Volatility & Risk
BioLargo has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.78, meaning that their average stock price is 78% more volatile than the S&P 500.
Institutional & Insider Ownership
0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares BioLargo and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -568.74% | 5.73% | -0.15% |
Summary
BioLargo peers beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.